Institutional Ownership
X4 Pharmaceuticals Inc
CUSIP 98420X103COMXFORQ1 2026
13D / 13G Filings
51
Schedule 13D/13G on record
Beneficial Filers
21
Distinct reporting persons
Largest Stake
11.1%
Max % of class reported
Institutional Holders
2
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
51 filings · latest Aug 14, 2025
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Aug 14, 2025 | Orbimed Advisors LLC | 13G/A | 1.7% | 134.9K | SEC |
| 2 | Jan 31, 2025 | The Vanguard Group | 13G/A | 4.8% | 8.20M | SEC |
| 3 | Nov 12, 2024 | Vanguard Group Inc | 13G/A | 5.0% | 8.44M | SEC |
| 4 | Nov 8, 2024 | Blackrock, Inc. | 13G | 6.7% | 11.21M | SEC |
| 5 | Nov 4, 2024 | Vanguard Group Inc | 13G/A | 5.0% | 8.44M | SEC |
| 6 | Oct 22, 2024 | Blackrock, Inc. | 13G | 6.7% | 11.21M | SEC |
| 7 | Feb 14, 2024 | Lincoln Park Capital Fund, LLC | 13G/A | 0.9% | 1.60M | SEC |
| 8 | Feb 14, 2024 | Orbimed Advisors LLC | 13G/A | 6.7% | 11.49M | SEC |
| 9 | Feb 14, 2024 | Acorn Bioventures, L.P. | 13G | 4.8% | 8.21M | SEC |
| 10 | Feb 13, 2024 | Bain Capital Life Sciences Fund, L.P. | 13G/A | 10.0% | 16.92M | SEC |
41 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for X4 Pharmaceuticals Inc.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Nea Management Company, LLC | 3.23M | $13.36M |
| 2 | Acorn Capital Advisors, LLC | 234.0K | $966.6K |